Karyopharm Therapeutics Presents Promising Selinexor Data at ASH

Karyopharm Therapeutics (Nasdaq: KPTI ) today announced the oral presentation of clinical data from an ongoing Phase 1 clinical trial of its lead oral SINE compound, Selinexor (KPT-330), in patients with relapsed and/or refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) at the 2013 American Society of Hematology